Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters

Curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal, and the persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is a key barrier that is hard to break through using the drugs currently approved for HBV treatment. Due to the accurac...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Kun, Feng, Jiangpeng, Liu, Xing, Wang, Hongyun, Li, Qiaohong, Li, Jiali, Xu, Tianmo, Sajid, Muhammad, Ullah, Hafiz, Zhou, Li, Zhou, Limin, Chen, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271097/
https://www.ncbi.nlm.nih.gov/pubmed/34254007
http://dx.doi.org/10.3389/fmicb.2021.665184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271097/
https://www.ncbi.nlm.nih.gov/pubmed/34254007
http://dx.doi.org/10.3389/fmicb.2021.665184

Ejemplares similares